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Background—The extent of influence of body mass index (BMIZ) and age on C-peptide at the 
diagnosis of type 1 diabetes is unknown.
Objective—We studied the influence of BMIZ and age on C-peptide measures at and soon after 
the diagnosis of type 1 diabetes (T1D).
Subjects—Data from Diabetes Prevention Trial-Type 1 (DPT-1) participants <18.0 years at 
diagnosis was analyzed.
Methods—Analyses examined associations of C-peptide measures with BMIZ and age in 2 
cohorts: oral glucose tolerance tests (OGTT) at diagnosis (n=99); mixed-meal tolerance tests 
(MMTT) <6 months after diagnosis (n=80). Multivariable linear regression was utilized.
Results—Fasting and area under the curve (AUC) C-peptide from OGTTs (n=99) at diagnosis 
and MMTTs (n=80) after diagnosis were positively associated with BMIZ and age (p<0.001 for 
all). Associations persisted when BMIZ and age were included as independent variables in 
regression models (p<0.001 for all). BMIZ and age explained 31%-47% of the variance of C-
peptide measures. In an example, two individuals with identical AUC C-peptide values had an 
approximate 5-fold difference in values after adjustments for BMIZ and age. The association 
between fasting glucose and C-peptide decreased markedly when fasting C-peptide values were 
adjusted (r=0.30, p<0.01 to r=0.07, n.s.).
Conclusions—C-peptide measures are strongly and independently related to BMIZ and age at 
and soon after the diagnosis of T1D. Adjustments for BMIZ and age cause substantial changes in 
C-peptide values, and impact the association between glycemia and C-peptide. Such adjustments 
can improve assessments of β-cell impairment at diagnosis.
Keywords
Type 1 diabetes; body mass index; age; C-peptide; children
INTRODUCTION
C-peptide indices are utilized to assess the loss of insulin secretion prior to and after the 
diagnosis of type 1 diabetes (T1D) in both clinical and research contexts. Clinically, these 
measures are used to differentiate T1D from type 2 diabetes and in guiding therapy. In 
addition, particularly in the United States, insurers have used C-peptide thresholds for 
determining whether insulin pumps and sensors should be covered. In the research setting, 
C-peptide measures are used to examine patterns of insulin loss in natural history studies (1), 
and as entry criteria and endpoints in clinical trials assessing interventions intended to 
prevent insulin loss (2–7).
In examining β-cell function for these purposes, it is essential to minimize other factors that 
could influence C-peptide levels apart from the pathology that is specific to T1D. Such 
factors include adiposity and age. Adiposity is known to be associated with insulin 
resistance (8,9). Although the direct influence of age on insulin resistance is less certain 
(10), age could influence insulin secretion by other mechanisms, such as possibly 
influencing β-cell mass (11). Thus, it is important to characterize the associations of C-
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peptide measures with indicators of adiposity such as BMI and age at the diagnosis of T1D 
to avoid a misinterpretation of β-cell function.
Since there is little information available regarding associations of C-peptide with BMI and 
age at the diagnosis of T1D, we have utilized Diabetes Prevention Trial-Type 1 (DPT-1) data 
to study the influence of BMI and age on C-peptide at the time of and soon after the 
diagnosis of T1D. In the DPT-1 study, a number of individuals were diagnosed by oral 
glucose tolerance testing which included C-peptide determinations. The findings presented 
below provide information that is relevant to assessments of β-cell function in both clinical 
and research settings.
METHODS
Subjects
Subjects who participated in the parenteral (12) and oral (13) insulin DPT-1 trials have 
previously been described in detail. All of the participants had islet cell autoantibodies and 
all were related to patients with T1D; neither the parenteral nor the oral insulin interventions 
showed efficacy. All participants included in the analysis were <18.0 years of age at 
diagnosis. Two analyses were performed from that cohort: a 2-hour oral glucose tolerance 
test (OGTT) analysis at the time of diagnosis, and a 2-hour mixed meal tolerance test 
(MMTT) analysis in the post-diagnostic period. For the OGTT analysis, all included were 
required to have BMI (kg/m2) measurements on the same date as the diagnostic OGTTs. 
Ninety-nine had BMI measurements on that date. Of those analyzed at diagnosis with 
OGTTs, 62 were in the parenteral insulin trial (intervention: 36; controls: 26) and 37 were in 
the oral insulin trial (intervention: 18; controls: 19). Criteria for inclusion in the MMTT 
analysis were the performance of MMTTs within 6 months after diagnosis and a BMI 
measurement within ±6 months of the MMTT. Of the 80 included in the MMTT analysis, 52 
were in the parenteral insulin trial (intervention: 30; controls: 22) and 28 were in the oral 
insulin trial (intervention: 11; controls: 17). The mean±SD interval from diagnosis to 
MMTTs was 0.24±0.10 years. Since each analysis had its own inclusion criteria, the 
participants could differ between the cohorts; overall, 53 individuals were included in both 
cohorts. DPT-1 was approved by institutional review boards at all participating sites, and 
written informed consents or assents as appropriate were obtained.
Procedures
As previously described (12,13), in both the parenteral and oral insulin DPT-1 trials, OGTTs 
were originally performed at 6-month (±3 months) intervals for diagnostic surveillance. 
After an oral glucose dose of 1.75 g per kilogram (maximum, 75 g of carbohydrate), fasting, 
30, 60, 90 and 120 minute samples were obtained for glucose and C-peptide measurements. 
All of those included in the analysis were diagnosed by American Diabetes Association 
criteria. When an OGTT was within the diabetic range (fasting glucose values ≥126 mg/dl 
and/or 2-hr glucose values ≥200 mg/dl), a second OGTT was to be performed within 60 
days unless clinically contraindicated. If the second OGTT was confirmatory, the age at the 
first diabetic OGTT was considered the age at diagnosis. The first diabetic OGTT (i.e., the 
diagnostic OGTT) was used for the OGTT analysis. For the MMTTs, glucose and C-peptide 
Sosenko et al. Page 3
Pediatr Diabetes. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
measurements were obtained before and after the consumption of a liquid formula meal 
(Sustacal/Boost, Mead Johnson Nutritionals; 6 kcal/kg body weight, maximum 360 kcal). 
Insulin dosing was held the morning of the OGTT until after test completion. Since children 
were analyzed, BMI Z-scores (BMIZ) were used for all analyses of BMI. The BMIZ values 
reflect BMI measures adjusted for age and sex based on Centers for Disease Control 
reference values (2000 growth charts). BMIZ is used as an indicator of the degree of 
adiposity.
Laboratory Measures
Plasma glucose levels were measured by the glucose oxidase method. C-peptide levels were 
measured by radioimmunoassay. Fasting C-peptide values in the undetectable range (<0.2 
ng/ml) were assigned a value of 0.1 ng/ml for the analyses. Three C-peptide measures were 
analyzed: fasting, area under the curve (AUC), and the 30-0 minute difference. The latter 
was included in the analysis, since it correlates with the first phase insulin response and 
declines during the latter stages of progression to T1D (14). The same C-peptide measures 
were used for the OGTT and MMTT analyses.
Data Analysis
Each of the analysis cohorts (OGTT and MMTT) were characterized using summary 
statistics, and two-sample t-tests and chi-square tests were used to compare factors and 
measures between groups of interest. Univariate and multivariable generalized linear 
regression models were used to examine associations of C-peptide variables with BMIZ and 
age. Models for each of the analysis cohorts were evaluated that adjusted for BMIZ alone, 
age alone, and for both. Pearson correlations were also utilized. Exploratory analyses 
supported the use of untransformed C-peptide measures; in addition, associations were 
similar when C-peptide values were log transformed.
To illustrate and further evaluate the influence of BMIZ and age on AUC C-peptide, 
coefficients for BMIZ and age for each of these fitted models were used to calculate an 
adjusted AUC C-peptide estimate from OGTTs at diagnosis and MMTTs after diagnosis. 
The influence of removing subject-specific BMIZ and age-related effects on AUC C-peptide 
was assessed by subtracting the subject-specific effects for BMIZ and age, according to the 
fitted models, from the actual observed AUC C-peptide value. We explored this delineation 
of effects added to the estimated AUC C-peptide that were specific to BMIZ and/or age for 
the individual difference from the average subject. In this context, those in the extremes for 
BMIZ or age in relation to the average cohort subject will have a greater adjustment to their 
AUC C-peptide than those whose BMIZ or age are near the overall average. An example of 
the formulaic approach for this functional adjustment is:
yι
∼ = yi − yι − yavg
yι
∼ = yi − β0 + β1BMIZi − β0 + β1BMIZ
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yι
∼ = yi − β0 + β1BMIZi − β0 − β1BMIZ
yι
∼ = yi − β0 − β0 + β1BMIZi − β1BMIZ
yι
∼ = yi − β1BMIZi − β1BMIZ
where yι = β0 + β1BMIZi is the predicted model-based estimate of AUC C-peptide for a 
specific subject and their corresponding BMIZ, yavg = β0 + β1BMIZ is the predicted model-
based estimate of AUC C-peptide using the mean BMIZ from the overall analysis cohort, 
and yi is the actual observed AUC C-peptide for the specific subject of interest. Thus, if our 
regression coefficient for BMIZ is 0.459, we would calculate the functional component of 
AUC C-peptide adjusted for BMIZ as yi − 0.459x BMIZi − BMIZ . These adjustments were 
utilized to assess the influence of such a correction and the possible roles BMIZ and age 
have on AUC C-peptide at or soon after the diagnosis of T1D. The same methodology was 
used to assess the influence of BMIZ and age on the fasting C-peptide. Pearson correlations 
were used to assess the impact of associations between glucose and C-peptide variables.
For the figure, data was categorized according to tertiles; comparisons were made between 
the highest and lowest groups. OGTT and MMTT AUCs were calculated with the 
trapezoidal rule. The SAS 9.2 version was used for the analyses. All p-values are two-sided 
with a significance level set at 0.05.
RESULTS
There were 99 DPT-1 participants with OGTTs at diagnosis (mean±SD age at diagnosis: 
11.3±3.3 years; mean±SD BMIZ at diagnosis: 0.42±1.13; 58% male) who were analyzed. 
Also, 80 DPT-1 participants were analyzed who had MMTTs within 6 months after 
diagnosis (age at MMTT: 11.8±3.4 years; BMIZ at MMTT: 0.52±1.08; 53% male). 
Characteristics of the participants are shown in Table 1, and values of C-peptide indices 
from the OGTTs and MMTTs are shown in Table 2. There were no differences between 
male and female participants in any of the C-peptide measures among the OGTT (male: 
n=57; female: n=42; p≥0.78 for differences) and the MMTT (male: n=38; female: n=42; 
p≥0.28 for differences) cohorts.
Regression coefficients for the associations of fasting C-peptide, 30-0 minute C-peptide 
difference, and AUC C-peptide from the OGTTs and MMTTs with BMIZ and age are shown 
in Table 3. There were substantial positive associations of the fasting and AUC C-peptide 
from the OGTTs with BMIZ and with age (p<0.001 for both). However, the 30-0 minute C-
peptide difference was not significantly associated with BMIZ or with age.
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The associations of the fasting and AUC C-peptide from the MMTTs with BMIZ and with 
age were also positive and significant (p<0.001 for all). Their magnitudes were similar to 
those for the OGTT associations. However, in contrast to the OGTTs, there was also a 
significant association of the 30-0 minute C-peptide difference with BMIZ (p<0.05). There 
were no significant associations of any of the C-peptide measures from the OGTTs or the 
MMTTs with gender.
Figure 1 shows C-peptide values for each OGTT time point according to BMIZ (A) and age 
(B) tertiles. The C-peptide values were significantly greater for the highest BMIZ tertile than 
for the lowest tertile at all OGTT time points (p<0.01 for all). The differences were even 
greater between the highest and lowest age tertiles (p<0.001 at all of the OGTT time points). 
For BMIZ, the values of the middle tertile were slightly higher than the values of the lowest 
tertile, whereas for age the values of the middle tertile were closer to the highest tertile.
Table 4 shows data from regression models with the C-peptide indices of the OGTTs and 
MMTTs as dependent variables, and BMIZ and age included together as independent 
variables for each model. Fasting and AUC C-peptide levels were significantly related to 
BMIZ and age in each model for both OGTTs and MMTTs. The R2 (the proportion of the 
variance explained by BMIZ and age together in the models) for the associations of the 
fasting and AUC C-peptide with BMIZ and age varied from 0.31 to 0.47 for the OGTTs and 
MMTTs. Notable were the similarities of the multivariable coefficients in Table 4 to the 
univariate coefficients in Table 3. These findings indicate that the associations with BMIZ 
and age were largely independent of each other.
To demonstrate the extent of influence of BMIZ and age on C-peptide levels at diagnosis, we 
adjusted AUC C-peptide values to mean BMIZ and mean age values of the 99 children in the 
OGTT cohort and the 80 children in the MMTT cohort (Table 5). In the example shown, a 
2.87 ng/ml/120 AUC C-peptide value of a 5 year-old child at the 10th BMIZ percentile of the 
OGTT cohort (BMIZ value=−1.13) would increase to an adjusted AUC C-peptide value of 
4.91 ng/ml/120. Conversely, a 2.87 ng/ml/120 AUC C-peptide value in a 17 year-old 
adolescent at the 90th BMIZ percentile would decrease to an adjusted AUC C-peptide value 
of 0.97 ng/ml/120. Thus, although the actual AUC C-peptide values were the same for each 
child, the adjusted AUC C-peptide value (i.e., after removal of the influence of BMIZ and 
age) was approximately 5-fold higher in the younger and thinner child. A large divergence 
was similarly evident for the adjusted AUC C-peptide from the MMTTs.
We examined the extent to which BMIZ and age influenced the impact of C-peptide on 
glycemia at diagnosis. Whereas there was a significant association of fasting glucose values 
(log transformed) with unadjusted fasting C-peptide levels (r=0.30, p<0.01), there was little 
association when fasting C-peptide levels were adjusted for BMIZ and age (r=-0.07, n.s.). 
There were significant associations of AUC glucose with both unadjusted and adjusted 
AUC-C-peptide levels; however, the association tended to be stronger (negatively) with 
adjusted AUC C-peptide levels (r=−0.37, p<0.001 for adjusted; r=−0.30, p<0.01 for 
unadjusted).
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DISCUSSION
The findings showed that at the diagnosis of T1D, an appreciable proportion of the variance 
of the fasting and AUC C-peptide from OGTTs was explained by BMIZ and age. Notably, 
the associations of the C-peptide indices with BMIZ and age were independent of each other 
in multivariable models. When the AUC C-peptide was adjusted for BMIZ and/or age, the 
C-peptide values differed markedly from the actual values.
There is an appreciable loss of C-peptide after diagnosis (15,16). Since MMTTs occurred on 
average about 3 months after the OGTTs, it appears that despite the loss of C-peptide after 
diagnosis, the magnitude of the association of C-peptide with BMIZ and age persists.
The independence of BMIZ and age in their associations with the C-peptide indices suggests 
that the basis for the associations differs between BMIZ and age. Evidence from prior 
studies are consistent with this finding. Whereas studies have consistently shown 
associations between insulin resistance and indicators of the degree of adiposity such as 
BMI in other populations (8,9), the relationship of insulin resistance with age is less certain 
(10). Since some β-cell characteristics are associated with age (11,17), it is possible that 
insulin secretion might be better sustained in older individuals who develop T1D. Age has 
been shown to be a mitigating factor for the risk of T1D (18) and for the loss of C-peptide 
levels soon after diagnosis (16).
The associations of C-peptide with BMIZ and age are clinically relevant, since C-peptide 
measurements are sometimes used to help differentiate the types of diabetes at diagnosis and 
to guide therapy. Also, low C-peptide values have been used as a criterion for providing 
insurance coverage of insulin pumps and glucose sensors. Thus, overweight and older 
children recently diagnosed with T1D could be less likely to obtain coverage than thinner 
and younger children.
These findings also have implications with regard to clinical trials evaluating interventions 
for preserving β-cell function in recently diagnosed T1D patients. Such trials have used the 
AUC C-peptide from MMTTs as endpoints (2–7). Adjustments of the AUC C-peptide have 
been made for age in those trials, but not for the degree of BMI. Moreover, the findings are 
also relevant to the selection of subjects for trials, since C-peptide levels below a minimum 
threshold are used as an exclusion criterion. Without appropriate adjustments for BMI and 
age, younger and thinner children would more likely be excluded from clinical trials than 
overweight adolescents.
Since adjustments of C-peptide for BMIZ and age essentially exclude the portion of C-
peptide that is attributable to those characteristics, we examined differences between 
unadjusted and adjusted C-peptide values with regard to their associations with glucose 
values. The analysis showed that the positive association between the fasting glucose and 
fasting C-peptide was especially impacted by the adjustment, indicating that the association 
was almost fully attributable to BMIZ and age. The adjustment of the AUC C-peptide 
resulted in a stronger inverse association with the AUC glucose, but the impact was smaller.
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Despite the substantial impact of BMIZ and age on C-peptide values, adjustments might not 
always be warranted. For example, adjustments for age could obscure the reasonable 
possibility that β-cell compromise is less severe at the diagnosis of T1D in older individuals. 
Thus, for natural history studies of β-cell decline, age stratification might be more 
appropriate than age adjustment. As more is learned about the bases for the associations of 
C-peptide with BMIZ and age, decisions regarding the need for adjustment can be made 
with more certainty.
The adjustments demonstrating the extent to which BMIZ and age influenced C-peptide 
levels do not necessarily generalize to other populations, since the coefficients for the 
associations could differ among populations. However, similar modeling procedures for 
adjustments could be utilized.
One of the limitations of the study was the lack of assessment of insulin resistance. We 
chose not to use indirect measures such as HOMA-IR, as they have not been validated in 
newly diagnosed T1D patients. In addition, since pubertal status was not ascertained at the 
time of diagnosis, we could not determine the extent of association between C-peptide 
indices and puberty. Insulin resistance has been shown to be associated with puberty (8). As 
a result of OGTT surveillance, it is likely that the diagnosis in DPT-1 occurred earlier than 
the typical diagnosis made clinically. Thus, the associations are not necessarily indicative of 
those at the time of a clinical diagnosis. Finally, since the analyses were cross-sectional, 
inferences could not be made on β-cell decline.
No prior studies have examined the impact of BMIZ and age on C-peptide indices from 
OGTTs at diagnosis, including their impact on associations between glucose and C-peptide. 
Recent studies (19,20) found that random C-peptide levels at diagnosis were higher in 
children with a greater degree of adiposity, and in older children. In a DPT-1 analysis, a 
correlation was observed between the AUC C-peptide from MMTTs and age in individuals 
at risk for T1D (21). A study of children and adult T1D patients within 3 months of their 
diagnosis found positive associations of the AUC C-peptide from MMTTs with BMIZ and 
age (16).
In conclusion, the findings indicate that BMIZ and age substantially and independently 
influence C-peptide levels at and soon after the diagnosis of T1D. These associations should 
be considered in both clinical and research settings. Although adjustments for BMIZ and age 
can add clarity to assessments of β-cell function, they should only be undertaken after 
determining their appropriateness for a particular objective.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Shown are mean AUC C-peptide levels during OGTTs according to BMIZ and age tertiles. 
Those in the highest tertiles of BMIZ and age had markedly higher AUC C-peptide levels 
than those in the lowest tertiles. For BMIZ, the values of the middle tertile were slightly 
higher than the values of the lowest tertile, whereas for age the values of the middle tertile 
were closer to the highest tertile. The ages of those in the middle BMIZ tertile (10.6±3.2 
years) tended to be lower than the ages of those in the lowest 11.4±3.6 and highest 11.8±3.1 
tertiles. After an adjustment for age, the AUC C-peptide values of the middle BMIZ tertile 
moved further from the lowest tertile (from 13% of the difference between the highest and 
lowest tertiles to 28% of the distance).
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Table 1
Characteristics of the OGTT and MMTT cohorts
OGTT Cohort (n=99) MMTT Cohort (n=80)
Age at Baseline (years) 9.0±3.1 9.3±3.3
Age at Diagnosis (years) 11.3±3.3 11.6±3.4
Age at MMTTs (years) -------- 11.8±3.4
Height (cm) 149.0±18.2 150.0±18.9
Height (Z-value) 0.55±0.99 0.33±0.84
Weight (kg) 46.0±19.2 47.6±19.1
Weight (Z-value) 0.61±1.04 0.55±0.99
BMI (kg/m2) 19.8±4.5 20.2±4.5
BMIZ 0.42±1.13 0.52±1.08
HbA1c (%) 6.1±0.8 --------
Gender (% Male) 57.6 52.5
mean±SD values shown except for Gender
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Table 2
Mean±SD C-peptide values of OGTTs at diagnosis and MMTTs within 0.5 years after diagnosis
OGTT (n=99) MMTT (n=80)
Fasting C-peptide (ng/ml) 1.34±0.89 1.02±0.63
30-0 Minute C-peptide Difference (ng/ml) 1.31±1.01 1.45±1.19
AUC C-peptide (ng/ml)/120 2.87±1.54 2.39±1.29
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Table 3
Regression coefficients and R2 (in parentheses) for univariate associations of C-peptide indices with BMIZ 
and age for OGTTs at diagnosis and for MMTTs within 0.5 years after diagnosis
OGTT (n=99) BMIZ Age (Years)
Fasting C-peptide (ng/ml) 0.41±0.07 (0.27)++ 0.13±0.02 (0.23)++
30-0 Minute C-peptide Difference (ng/ml) 0.07±0.09 (0.01) 0.05±0.03 (0.03)
AUC C-peptide (ng/ml)/120 min 0.46±0.13 (0.11)++ 0.23±0.04 (0.24)++
MMTT (n=80)
Fasting C-peptide (ng/ml) 0.25±0.06 (0.19)++ 0.07±0.02 (0.15)++
30-0 Minute C-peptide Difference (ng/ml) 0.31±0.12 (0.08)+ 0.04±0.04 (0.02)
AUC C-peptide (ng/ml)/120 min 0.44±0.13 (0.13)++ 0.15±0.04 (0.16)++
+p<0.05;
++p<0.001
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